According to the vaccine makers, the third dose of the Pfizer-BioNTech vaccine against coronavirus disease (Covid-19) demonstrated 95.6 percent efficacy compared to those who did not receive a booster. Pfizer-BioNTech announced the results of a Phase 3 trial evaluating the efficacy and safety of a 30-g booster dose of the mRNA-based Pfizer-BioNTech Covid-19 Vaccine, the same dosage strength as those in the primary series, on Thursday.
"These findings provide additional evidence of the benefits of boosters as we strive to keep people well-protected against this disease," said Pfizer CEO Albert Bourla in a statement.
The booster dose trial included over 10,000 people who had completed the primary two-dose series of the Pfizer Covid-19 vaccine. Half of the participants in the trial were given a 30-g booster dose, while the other half were given a placebo. The researchers found five cases of Covid-19 in the booster dose group and 109 cases in the placebo group.
According to the study's multiple subgroup analyses, booster dose efficacy was consistent regardless of age, gender, race, ethnicity, or comorbid conditions.
The partners from the United States and Germany are the first to publish efficacy results from any randomized, controlled Covid-19 vaccine booster trial.
"We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic, in addition to our efforts to increase global access and uptake among the unvaccinated," Bourla added.
Pfizer-BioNTech and Moderna Covid vaccines are at the heart of the pandemic immunization program in the United States.
The US Food and Drug Administration (FDA) has already approved the third dose of Pfizer Covid vaccine for emergency use in people 65 and older, as well as all adults at high risk of severe Covid-19 and those who have frequent institutional or occupational exposure to the virus.